About Vistagen Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.vistagen.com/
Frequently Asked Questions
What is the 52-week range for VTGN?
The 52-week high is $5.14 and the 52-week low is $0.198.
What is the P/E ratio for VTGN?
The P/E ratio data is currently unavailable.
What is the dividend yield for VTGN?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -152.59%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -2702.64%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.64.
Analyst Recommendation Trends
Wall Street analyst consensus for VTGN over the last few months:
Latest VTGN News
Vasomotor Symptoms Market Poised for Growth Through 2036, Driven by Rising Adoption of Hormonal and Non-Hormonal Therapies | DelveInsight
Recently published Vasomotor Symptoms Market Insights report includes a comprehensive understanding of current treatment practices, vasomotor symptoms emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
2 Falling Stocks Call Traders Are Targeting Today
Call traders are targeting META and VTGN
SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)
SRX has added ONCO in anticipation of Realbotix LLC acquisition closing. Believes Vinci AI Vision system is extremely undervalued and misunderstood, with multiple potential applications in defense, ranging from drones for facial recognition to body cameras.NORTH PALM BEACH, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operat
Vistagen Presents Fasedienol Subgroup Data in Severe Social Anxiety Disorder
Vistagen (NASDAQ:VTGN) presented exploratory clinical data for its investigational fasedienol nasal spray at Psych Congress 2026 in New Orleans on September 24, reporting findings from subgroup analyses involving participants with very severe social anxiety disorder. The findings were derived from two randomised, double-blind, placebo-controlled clinical trials and included one post-hoc analysis and one prespecified subgroup analysis.
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Apimeds Pharmaceuticals (AMEX:APUS) shares increased by 162.4% to $6.01 during Thursday's regular session. The market value of their outstanding shares is at $3.4 million. Surrozen (NASDAQ:SRZN) stock
Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder
Exploratory research results presented at Psych Congress 2026 in New Orleans Full poster presentation can be found on “Publications” section of Company’s website SOUTH SAN FRANCISCO, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, presented positive exploratory data at Psych Congress 2026 in New Orle
Vistagen Presents Exploratory Data At Psych Congress 2026 Highlighting Potential Efficacy Signal For Phase 3 Fasedienol Nasal Spray In Patients With Very Severe Social Anxiety Disorder
Exploratory research results presented at Psych Congress 2026 in New OrleansFull poster presentation can be found on "Publications" section of Company’s websiteSOUTH SAN FRANCISCO, Calif., Sept. 24, 2026 (GLOBE
Let's take a look at the stocks that are in motion in today's session.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.
Discover the most active stocks in Wednesday's session.
Get a pulse on the US markets on Wednesday by checking out the most active stocks in today's session. Discover the stocks that are leading the way in terms of trading volume and market activity.
Wednesday's session: top gainers and losers
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
Gapping stocks in Wednesday's session
Let's have a look at the gap up and gap down stocks in today's session.
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Artelo Biosciences (NASDAQ:ARTL) shares rose 216.1% to $13.12 during Wednesday's regular session. The market value of their outstanding shares is at $2.2 million. Vistagen Therapeutics (NASDAQ:VTGN) shares
Stay updated with the stocks that are on the move in today's pre-market session.
As the US market prepares to open on Wednesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Penny Stock Vistagen Analyst Highlights Caution after Anxiety Data
Vistagen reports positive preliminary Phase 3 data showing fasedienol nasal spray reduces social anxiety with strong safety results.
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers IM Cannabis (NASDAQ:IMCC) stock rose 56.3% to $6.47 during Wednesday's pre-market session. The company's market cap stands at $2.5 million. Vistagen Therapeutics (NASDAQ:VTGN) shares increased by
Why Worthington Enterprises Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
Worthington Enterprises surged 15.9% premarket after beating Q1 EPS and sales estimates; Wheeler REIT led gainers, while Jaguar Health and Biomea fell.
Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Fasedienol nasal spray was well-tolerated in patients with social anxiety disorder with no new drug-related safety findings after as-needed use for up to 12 months Clinically relevant improvement in social anxiety over time was observed on both clinician-administered and patient-reported scales over four months PALISADE-4 OLE data add to growing body of evidence supporting fasedienol’s potential to address social anxiety disorder in anxiety-provoking social and performance situations in everyday
Vistagen to Present at Psych Congress 2026
Poster presentation highlights positive efficacy signal for fasedienol nasal spray in study participants with very severe social anxiety disorderSOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present data highlighting a positive efficacy signal for its Ph
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-07-29 | Williamson Douglas J | +40,826 | - | - |
| 2026-06-30 | Adler Reid G. | +36,818 | $0.1921 | $7,073 |
| 2026-06-30 | Tressler Nick B. | +11,712 | $0.1921 | $2,250 |
| 2026-06-30 | Singh Shawn | +36,818 | $0.1921 | $7,073 |
| 2026-05-18 | Angelov Angel S | +150,000 | - | - |
| 2026-04-07 | Cote Elissa S. | +75,000 | - | - |
| 2026-04-07 | Prince Joshua S. | +56,248 | - | - |
| 2026-04-07 | Prince Joshua S. | +18,752 | - | - |
| 2026-04-07 | Adler Reid G. | +56,247 | - | - |
| 2026-04-07 | Adler Reid G. | +18,753 | - | - |
| 2026-04-07 | Tressler Nick B. | +75,000 | - | - |
| 2026-04-07 | Singh Shawn | +71,268 | - | - |
| 2026-04-07 | Singh Shawn | +3,732 | - | - |
| 2025-12-31 | Prince Joshua S. | +4,386 | $0.5626 | $2,468 |
| 2025-12-01 | Tressler Nick B. | +150,000 | - | - |
| 2025-10-27 | Edick Paul R | +35,200 | - | - |